UriVArx® was evaluated in two clinical studies. Both studies confirmed the safety and the benefit of UriVArx® in supporting healthy bladder function and normal urinary frequency.

The first study compared the efficacy of crataeva and horsetail to UriVarx®. UriVArx® was proven to be more effective in reducing the frequency of daily urination and superior in reducing nocturia compared to crataeva and horsetail after one month of treatment.

Clinical Data Chart

UriVArx® was evaluated in an in an 8-week, double-blind, randomized, placebo-controlled, clinical study. UriVArx® was assessed in participants to determine the effect on urinary frequency and urgency. Data was collected at 2, 4, and 8 weeks. The primary outcome measure was self-reported urinary frequency defined as the number of voluntary diurnal and/ or nocturnal micturitions. Reported baseline measurements were similar between groups. At week 8, urinary frequency during the day was significantly lower in subjects administered UriVArx® compared to placebo (Figure 3). Similarly, episodes of nocturia and urgency were significantly fewer versus placebo (Figures 4 & 5). Significant improvements in quality of life were reported at end of study in comparison to placebo.

Clinical Data Chart

There were no serious side effects reported, and 84% of participants confirmed they had benefited from treatment.*

There were no adverse events leading to discontinuation.